SERUM LEVELS OF SOLUBLE CD30 MOLECULE (KI-1 ANTIGEN) IN HODGKINS-DISEASE - RELATIONSHIP WITH DISEASE-ACTIVITY AND CLINICAL STAGE

In all cases of Hodgkin's disease (HD) Reed‐Sternberg (RS) cells express the CD30 antigen. It has been recently demonstrated that this molecule can be released from the cell membrane of CD30 + neoplastic cells in a soluble form (sCD30), detectable in culture supernatants and body fluids. In this paper we investigated by an immunoassay the serum levels of sCD30 in 58 patients with HD, in order to define the possible relationship of this molecule to the clinical and pathological findings. sCD30 molecule was found at detectable levels in 24 out of 50 patients (48%) with active disease, whereas it was always absent in control sera and in cases in complete remission. Among the patients with active HD, the incidence and mean values of detectable levels (±SEM) of sCD30 were higher in cases with progressive or relapsing disease (61.5%, mean 458±190 U/ml) as compared to those at presentation (43.2%, mean 116 ± 3 3 U/ml). Among the cases at presentation, detectable levels were observed more often in patients with advanced stages (III+IV: 61%) and constitutional symptoms (‘B’: 61‐5%) than in early stages (I+11: 26%) and without symptoms (‘A’: 33.3%). In addition, higher mean values were found in stages III+IV (182±60 U/ml) and in ‘B’cases (208±73 U/ml) than in stages I+II (65 ± 30 U/ml) or ‘A’patients (64 ± 26 U/ ml). The above findings suggest a possible role for the sCD30 as a tumour marker in HD. Copyright © 1990, Wiley Blackwell. All rights reserved